Semaglutide 5mg/10mg Research Peptide

For Research Purposes Only. Not approved for human consumption.

Semaglutide Research Peptide 5mg

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk, representing the current standard for single-mechanism metabolic peptide research. It mimics endogenous GLP-1 with 94% homology but with extended half-life (~165 hours) due to albumin binding via a C-18 fatty di-acid side chain. With extensive Phase 3 data across diabetes (SUSTAIN trials) and obesity (STEP trials), Semaglutide serves as a benchmark comparator for researchers studying newer metabolic peptides including Tirzepatide and Retatrutide.

Research Applications

• GLP-1 receptor biology and signaling research
• Diabetes and glucose metabolism studies
• Obesity and weight regulation research
• Gastric motility and satiety mechanism studies
• Comparative metabolic peptide efficacy studies

Quality Specifications

• Purity: ≥98% (HPLC verified)
• Compound: Semaglutide
• Molecular Weight: 4113.6 Da
• Form: Lyophilized powder
• Storage: -20°C, protect from light
• COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: How does Semaglutide differ from native GLP-1?
A: 94% homology to human GLP-7-37 but with a C-18 fatty di-acid side chain enabling albumin binding. This extends half-life from minutes to ~165 hours, allowing weekly administration in research.

Q: What is Semaglutide's research significance?
A: Extensive Phase 3 data makes it the benchmark GLP-1 agonist. Researchers use it as a comparator when studying newer compounds like Tirzepatide (dual agonist) and Retatrutide (triple agonist).

Q: How does Semaglutide work mechanically?
A: Activates GLP-1 receptors in the pancreas (glucose-dependent insulin secretion), hypothalamus (appetite regulation), and GI tract (delayed gastric emptying).